GlassScriptPhysician profile
Thomas Patrick Demarini
NPI 1407831696
$59,191.42
in general payments reported to CMS, 2019-2025
49 companies · $24.92 in 2025
The $24.92 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,613 · 2020: $2,078 · 2021: $11K · 2022: $37K · 2023: $1,423 · 2024: $49.65 · 2025: $24.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,270 · Education: $150 · Travel and Lodging: $76.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,270.45 |
| Education | $150.00 |
| Travel and Lodging | $76.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $45,263.91 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,801.18 | 2019-2023 | Ofev |
| Astrazeneca Pharmaceuticals LP | $1,075.22 | 2019-2023 | Tezspire, Breztri, Fasenra |
| Harmony Biosciences LLC | $620.25 | 2020-2023 | Wakix |
| Actelion Pharmaceuticals US, INC. | $559.45 | 2019-2023 | Opsumit |
| Jazz Pharmaceuticals INC. | $538.89 | 2019-2023 | |
| Grifols USA, LLC | $401.64 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $384.39 | 2019-2021 | |
| Mylan Specialty L.P. | $326.62 | 2019-2022 | |
| Insmed, INC. | $306.05 | 2019-2023 | Arikayce |
| Daiichi Sankyo INC. | $288.12 | 2019-2023 | Injectafer |
| Genzyme Corporation | $244.29 | 2019-2023 | |
| United Therapeutics Corporation | $218.81 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $169.39 | 2019-2023 | Dupixent |
| Teva Pharmaceuticals USA, INC. | $169.08 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Demarini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.